NCT06707129 Establishment of Precise Histological Evaluation Criteria for NASH Fibrosis Reversal
| NCT ID | NCT06707129 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Municipal Administration of Hospitals |
| Condition | Non-alcoholic Fatty Liver Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-08-01 |
| Primary Completion | 2027-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2024-08-01 with a primary completion date of 2027-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Collect confirmed cases of NAFLD patients and enroll them in the study. Select patients with NASH and fibrosis stage F2-4 confirmed by liver biopsy, and collect clinical and pathological data for relevant evaluation and definition. Establish a NASH "fibrosis reversal" pathological evaluation system, based on a new reversal standard, establish non-invasive alternative indicators, and observe indicators.
Eligibility Criteria
Inclusion Criteria: * Aged between 18 and 70 years at the time of liver biopsy; * Gender is not limited; * Hepatic perforation suggested that NASH complicated with fibrosis stage F2-4; * Signed written informed consent. Exclusion Criteria: * Combined HCV infection, HIV infection, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease Disease, drug-induced liver injury and other chronic liver diseases; * Women during pregnancy; * There are the following conditions before liver perforation: HCC or possible HCC (imaging suggests malignant liver occupation); decompensation of cirrhosis (ascites, hepatic encephalopathy, gastrointestinal bleeding, hepatorenal syndrome, etc.); Patients with other malignant tumors; Recipients of liver transplantation; * Patients considered by the investigator to be unsuitable for this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06707129 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Non-alcoholic Fatty Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06707129 currently recruiting?
Yes, NCT06707129 is actively recruiting participants. Contact the research team at wuhm2000@sina.com for enrollment information.
Where is the NCT06707129 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06707129 clinical trial?
NCT06707129 is sponsored by Beijing Municipal Administration of Hospitals. The trial plans to enroll 50 participants.